Gramicidin

Summary

Gramicidin (CHEMBL1201469) is an approved unknown (ATC R02AB30); indicated across 1 condition including hordeolum.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: R02AB30
• Indications: 1 condition

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201469
Name	Gramicidin
Type	Unknown
Max phase	4
ATC	R02AB30

Also known as: Gramicidin, Gramicidin component of neo-polycin, Gramicidin d, Gramicidina, Gramicidine, Gramicidins, NSC-757043, GRAMICIDIN

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Thromboxane-A synthase, Tyrosine-protein kinase Fyn, Substance-K receptor, Endothelin-1 receptor, Tyrosine-protein kinase Lck, Melanocortin receptor 4, Melanocortin receptor 5.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TBXAS1	6.11	IC50	774	nM	CHEMBL_ACT_7670612
LCK	5.96	IC50	1094	nM	CHEMBL_ACT_7670576
TACR2	5.82	Ki	1521	nM	CHEMBL_ACT_7670609
EDNRA	5.74	Ki	1835	nM	CHEMBL_ACT_7668434
MC5R	5.72	Ki	1888	nM	CHEMBL_ACT_7668482
MC5R	5.7	IC50	2013	nM	CHEMBL_ACT_7668481
EDNRA	5.53	IC50	2983	nM	CHEMBL_ACT_7668433
MC4R	5.5	Ki	3186	nM	CHEMBL_ACT_7668480
MC4R	5.48	IC50	3313	nM	CHEMBL_ACT_7668479
FYN	5.48	IC50	3331	nM	CHEMBL_ACT_7670572
TACR2	5.34	IC50	4564	nM	CHEMBL_ACT_7670608

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hordeolum	3	MONDO:0005800	EFO:0007315

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).